

Liana S Rosenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/67195/publications.pdf>

Version: 2024-02-01

58
papers

2,693
citations

331670

21
h-index

206112

48
g-index

61
all docs

61
docs citations

61
times ranked

3847
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life Changes Following the Onset of Cerebellar Ataxia: Symptoms and Concerns Self-reported by Ataxia Patients and Informants. <i>Cerebellum</i> , 2022, 21, 592-605.	2.5	13
2	The association between educational attainment and SCA 3 age of onset and disease course. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 99-102.	2.2	3
3	Neuropsychiatric Symptoms as a Reliable Phenomenology of Cerebellar Ataxia. <i>Cerebellum</i> , 2021, 20, 141-150.	2.5	12
4	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. <i>Lancet Neurology</i> , The, 2021, 20, 107-116.	10.2	62
5	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 958-968.	1.2	17
6	The Cerebellum and Implicit Sequencing: Evidence from Cerebellar Ataxia. <i>Cerebellum</i> , 2021, 20, 222-245.	2.5	13
7	Movement Disorders Virtual Fellowship Training in Times of Coronavirus Disease 2019: A Single-Center Experience. <i>Telemedicine Journal and E-Health</i> , 2021, 27, 1160-1165.	2.8	5
8	Stress and mindfulness in Parkinson's disease – a survey in 5000 patients. <i>Npj Parkinson's Disease</i> , 2021, 7, 7.	5.3	35
9	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	21.4	198
10	Dysregulated miRNAs mark Parkinson's disease progression. <i>Nature Aging</i> , 2021, 1, 241-242.	11.6	0
11	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. <i>JAMA Neurology</i> , 2021, 78, 312.	9.0	83
12	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 469-480.	1.3	10
13	Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117417.	0.6	11
14	Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors. <i>Movement Disorders</i> , 2021, 36, 2922-2931.	3.9	34
15	Evaluation of the Sensitivity and Reproducibility of Targeted Proteomic Analysis Using Data-Independent Acquisition for Serum and Cerebrospinal Fluid Proteins. <i>Journal of Proteome Research</i> , 2021, 20, 4284-4291.	3.7	6
16	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	7.4	80
17	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	16.0	11
18	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	2.4	12

#	ARTICLE	IF	CITATIONS
19	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020, 19, 71-80.	10.2	94
20	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020, 143, 234-248.	7.6	149
21	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	3.7	23
22	Development of a novel method for the quantification of tyrosine 39 phosphorylated α - and β -synuclein in human cerebrospinal fluid. <i>Clinical Proteomics</i> , 2020, 17, 13.	2.1	10
23	Dysphagia in spinocerebellar ataxias type 1, 2, 3 and 6. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116878.	0.6	3
24	The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 37-43.	2.2	16
25	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 449-461.	3.7	44
26	Differential Changes in Arteriolar Cerebral Blood Volume between Parkinson's Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorder: An Exploratory Study. <i>Tomography</i> , 2020, 6, 333-342.	1.8	7
27	Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale. <i>Neurodegenerative Diseases</i> , 2020, 20, 139-146.	1.4	1
28	Visuospatial Organization and Recall in Cerebellar Ataxia. <i>Cerebellum</i> , 2019, 18, 33-46.	2.5	13
29	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
30	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.4	29
31	Assessment of APOE in atypical parkinsonism syndromes. <i>Neurobiology of Disease</i> , 2019, 127, 142-146.	4.4	21
32	Genetic analysis of neurodegenerative diseases in a pathology cohort. <i>Neurobiology of Aging</i> , 2019, 76, 214.e1-214.e9.	3.1	25
33	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	3.1	13
34	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 29-36.	2.2	94
35	Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, e131-e139.	2.7	9
36	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018, 47, 50-56.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 31-38.	1.5	9
38	05â€³â€³04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1646.	0.8	0
39	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	3.7	330
40	Poly(ADP-ribose) drives pathologic Î±-synuclein neurodegeneration in Parkinsonâ€™s disease. <i>Science</i> , 2018, 362, .	12.6	317
41	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 108-109.	2.2	1
42	Finding useful biomarkers for Parkinsonâ€™s disease. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
43	Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 8-14.	2.2	37
44	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. <i>Biomarkers in Medicine</i> , 2017, 11, 451-473.	1.4	49
45	Changes in Verbal Fluency in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 84-89.	1.5	13
46	The NINDS Parkinson's disease biomarkers program. <i>Movement Disorders</i> , 2016, 31, 915-923.	3.9	83
47	Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 107-114.	2.2	21
48	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 102-106.	2.2	8
49	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	9.0	185
50	<i>C9orf72</i> Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. <i>Neurodegenerative Diseases</i> , 2016, 16, 370-372.	1.4	8
51	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2016, 94, 55-62.	4.4	55
52	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in <sc>P</sc> Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	3.9	158
53	Cognitive profile of <i>LRRK2</i>â€related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	3.9	64
54	A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. <i>Journal of NeuroVirology</i> , 2013, 19, 432-441.	2.1	17

#	ARTICLE	IF	CITATIONS
55	Clinical Reasoning: A 57-year-old man with jaw spasms. <i>Neurology</i> , 2013, 80, e104-7.	1.1	0
56	The Benefits of Exercise in Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 156.	9.0	16
57	The Preoperative Neurological Evaluation. <i>Neurohospitalist, The</i> , 2013, 3, 209-220.	0.8	11
58	Neuropathologies underlying acquired language disorders. , 2012, , 37-60.		1